If you have been reading about Melanotan II and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
However, it is possible that some isotopes that are now considered stable will be revealed to decay with extremely long half-lives (as happened with bismuth). For each of the 80 stable elements, the number of stable isotopes is given. Only 90 isotopes are stable against any possible decay, and an additional 161 are energetically unstable (see List of nuclides) but have never been observed to decay. Thus, 251 isotopes (nuclides) are stable by definition (including an excited state, tantalum-180m, for which no decay has yet been observed). In April 2019 it was announced that the half-life of xenon-124 had been measured to 1.8 × 1022 years. This is the longest half-life directly measured for any unstable isotope; only the (indirectly measured) half-life of tellurium-128 is longer. Of the chemical elements, only 1 element (tin) has 10 such stable isotopes, 5 have 7 stable isotopes, 7 have 6 stable isotopes, 11 have 5 stable isotopes, 9 have 4 stable isotopes, 5 have 3 stable isotopes, 16 have 2 stable isotopes, and 26 have 1 stable isotope. Additionally, 31 nuclides of the naturally occurring elements have unstable isotopes with a half-life long enough to have survived for the age of the Solar System (108 years or more), and an additional four such nuclides represent three elements (bismuth, thorium, uranium) having no stable isotope. These 35 radioactive naturally occurring nuclides comprise the radioactive primordial nuclides. The total number of primordial nuclides is then 251 (the stable nuclides) plus the 35 radioactive primordial nuclides, for a total of 286.
== Other animals == Bovine somatotropin occurs in the pituitary of cattle and differs in structure from human pituitary growth hormone and is biologically inactive in the human being. Bovine somatotropin aids in regulating the amount of milk produced. Recombinant bovine somatotropin (rBST) is a hormone that is injected in cows that increases milk production.
=== Christian: The Angry Couch Potato === First aired 5 April 2009 Mayhem helps out Cameron and Brian, by dropping Conor "Hurricane" Heun in the cage with Christian, a lazy, couch potato with a thirst for the pain of others.
=== Privacy and fungibility === Bitcoin is pseudonymous, with funds linked to addresses, not real-world identities. While the owners of these addresses are not directly identified, all transactions are public on the blockchain. Patterns of use, like spending coins from multiple inputs, can hint at a common owner. Public data can sometimes be matched with known address owners. Bitcoin exchanges might also need to collect personal data as per legal requirements. For enhanced privacy, users can generate a new address for each transaction. In the bitcoin network, each bitcoin is treated equally, ensuring basic fungibility. However, users and applications can choose to differentiate between bitcoins. While wallets and software treat all bitcoins the same, each bitcoin's transaction history is recorded on the blockchain. This public record allows for chain analysis, where users can identify and potentially reject bitcoins from controversial sources. For example, in 2012, Mt. Gox froze accounts containing bitcoins identified as stolen.
For services to the Care of the Victims of Torture. Professor Howard Anthony Barnes, Senior Scientist, Unilever Research. For services to Science and Technology. Alison Mary Hore Bastard. For services to the Magistracy in South Devon. Elizabeth Mary Bavidge, Co-Chair, Women's National Commission. For services to Women's Issues. The Very Reverend Trevor Randall Beeson. For services to the Church of England, particularly as Dean of Winchester Cathedral. Hugh Richard Belshaw, lately Finance Director, Oxfam. For Charitable services. Professor Martin Biddle. For services to the Royal Commission on the Historical Monuments of England. Robin Edgar Birley, , Director, Vindolanda Trust. For services to Conservation. Cilla Black. For services to Entertainment. David Blackburn, Senior Management Pay Band 2, the Employment Service, Department for Education and Employment. Peter Kenneth Blair, Managing Director, Racal Research Ltd. For services to the Radar Industry. Victor Harold Blake, Founder Chairman, The London Underwriting Centre (LUC). For services to the Insurance Industry. Charles Conrad Blakey, , Chairman, Kent Probation Committee. For services to the Rehabilitation of Offenders. Ian James Blakey, Director General, British Iron and Steel Producers' Association. For services to Industry. Jennifer Blunt. For services to Medical Research Ethics. Christopher Arthur Booy, Chief Executive, Symonds Group Ltd. For services to the Ministry of Defence. Geoffrey Malcolm Bray, Chairman, Kazakh and Uzbek British Trade and Industry Councils. For services to Export.
Sources: en.wikipedia.org
This included Meskigal, as governor of the city-state of Adab and Karsum governor of the unlocated Niqqum (suggested to be modern Khanaqin). Another was Lugal-ushumgal of Lagash. Several inscriptions of Lugal-ushumgal, who went on to serve the successor of Naram-Sin, Shar-Kali-Sharri, are known, particularly seal impressions, which refer to him as governor of Lagash and at the time a vassal (𒀵, arad, "servant" or "slave") of Naram-Sin.
=== Death of Asa Gilbert Eddy === Eddy's husband, Asa Gilbert Eddy, died of heart disease on June 4, 1882, shortly after the move to Boston. She invited the Boston Globe to her home on the day of his death to allege that he had been killed by malicious animal magnetism, courtesy of "certain parties here in Boston, who had sworn to injure them." The Globe wrote:
==== Subepidermal calcified nodule ==== Subepidermal calcified nodule is characterized by calcification of the skin resulting from the deposition of calcium and phosphorus, occurring most frequently as one or a few skin lesions on the scalp or face of children.
== Epidemiology == McLeod syndrome is present in 0.5 to 1 per 100,000 of the population. McLeod males have variable acanthocytosis due to a defect in the inner leaflet bilayer of the red blood cell, as well as mild hemolysis. McLeod females have only occasional acanthocytes and very mild hemolysis; the lesser severity is thought to be due to X chromosome inactivation via the Lyon effect. Some individuals with McLeod phenotype develop myopathy, neuropathy, or psychiatric symptoms, producing a syndrome that may mimic chorea.
Sources: en.wikipedia.org
== Ecology == Xanthoria parietina demonstrates a range of physiological and morphological adaptations that facilitate its survival in diverse habitats. Populations in drier, more exposed habitats produce longer-chain surface hydrocarbons (alkanes), whereas those in more humid, cooler regions synthesize shorter-chain alkanes—a response that helps reduce water loss, similar to adaptations seen in vascular plants. Its thallus morphology is plastic; forms in moist stream beds tend to be semi-erect and orange-yellow, whereas those in drier, sun-exposed sites are more compact and darker orange. These differences appear to be induced by environment conditions rather than genetic differences.
==== Warp Drive Bio ==== In 2012, Verdine founded Warp Drive Bio with cofounders George Church and James Wells. The company maps the genomes of soil-dwelling microbes in the search for potential treatments for drug-resistant ailments. In 2013, Verdine became full-time CEO of Warp Drive Bio, then handed the CEO position to Lawrence Reid in 2016 in order to found two new startups, FogPharma and LifeMine.
The city currently has a large number of rail and road work sites. Although this activity has increased as a result of the 2006 Winter Olympics, parts of it had long been planned. Some of the work sites deal with general roadworks to improve traffic flow, such as underpasses and flyovers, but two projects are of major importance and will radically change the shape of the city. One is the Spina Centrale ('Central Spine') project which includes the doubling of a major railway crossing the city, the Turin-Milan railway locally known as Passante Ferroviario di Torino ('Turin Railway Bypass'). The railroad previously ran in a trench, which will now be covered by a major boulevard running from north to south of Turin, in a central position along the city. Porta Susa, on this section, will become Turin's main station to substitute the terminus of Porta Nuova with a through station. Other important stations are Stura, Rebaudengo, Lingotto and Madonna di Campagna railway stations, though not all of them belong to the layout of the Spina Centrale.
==== ATP replenishment by nucleoside diphosphate kinases ==== ATP can also be synthesized through several so-called "replenishment" reactions catalyzed by the enzyme families of nucleoside diphosphate kinases (NDKs), which use other nucleoside triphosphates as a high-energy phosphate donor, and the ATP:guanido-phosphotransferase family.
During the final years of the 20th century, Gaddafi—frustrated by the failure of his pan-Arab ideals and the refusal of the Arab world to challenge the international air embargo imposed on Libya—increasingly rejected Arab nationalism in favour of pan-Africanism, emphasizing Libya's African identity. In a 1998 interview, Gaddafi claimed that "the Arab world is finished" and expressed his wish for Libya to become a "black country". From 1997 to 2000, Libya initiated cooperative agreements or bilateral aid arrangements with 10 African states, and in 1999 joined the Community of Sahel–Saharan States (CEN–SAD). In June 1999, Gaddafi visited Mandela in South Africa, and the next month attended the OAU summit in Algiers, calling for greater political and economic integration across the continent and advocating the foundation of a United States of Africa. He became one of the founders of the African Union (AU), initiated in July 2002 to replace the OAU. At the opening ceremonies, he called for African states to reject conditional aid from the developed world, a direct contrast to the message of South African President Thabo Mbeki. There was speculation that Gaddafi wanted to become the AU's first chair, raising concerns within Africa that this would damage the Union's international standing, particularly with the West.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.